PRIMARY OBJECTIVES: I. To establish the safety and efficacy of pazopanib hydrochloride in patients with differentiated, medullary, or anaplastic thyroid cancer. SECONDARY OBJECTIVES: I. To assess the impact of pazopanib hydrochloride on serum and plasma VEGF levels. II. To explore the potential relationship between changes in thyroglobulin levels and tumor response in patients with advanced differentiated thyroid cancer known to be thyroglobulin antibody negative. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 6 months or until 3 years after registration.
Last updated: 04/01/2013